Product news

Share this article:

Bayer HealthCare Pharmaceuticals announced that a reformulation of the liquid Leukine  (sargramostim) has been approved by FDA and is now available for patients and physicians in the US. The new formulation does not contain EDTA (edetate disodium), which was in the product's liquid 500 mcg vial manufactured from January 2006 to January 2008.

Tibotec Therapeutics announced the availability of a new 600 mg tablet strength for Prezista (darunavir), a protease inhibitor (PI). The new dosage strength was approved by the FDA in February. The recommended oral dose of PREZISTA for treatment-experienced adult patients with HIV-1 is 600 mg (one 600 mg tablet or two 300 mg tablets) taken twice daily with ritonavir 100 mg, in combination with other antiretroviral agents, and with food. The 300 mg tablet will remain available as long as there is sufficient demand for it.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.